HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · Frag 17-23 (TB-500 Fragment 17-23, Ac-LKKTETQ)
Thymosin β4 active fragment · research-use
Research-grade Ac-LKKTETQ heptapeptide — the actin-binding active core of thymosin beta-4 — supplied lyophilized with a per-batch HPLC/MS COA for labs and private-label brands.
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | Frag 17-23 (TB-500 Fragment 17-23, Ac-LKKTETQ) |
|---|---|
| CAS number | 885340-08-9 |
| Molecular formula | C38H68N10O14 |
| Molecular weight | 889.0 g/mol (889.02) |
| Sequence | Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ) |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 10mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Distribution scope | Research use, worldwide |
| Storage | Lyophilized powder is stable sealed at -20°C, protected from light and moisture; -80°C for long-term storage. After reconstitution with bacteriostatic water, keep refrigerated at 2-8°C and use within a short window for research work. |
| Tier | Quantity | Lead time |
|---|---|---|
| OEM lot | 50 kits (500 vials) | 3–7 days |
| Production lot | 500–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
Frag 17-23 (Ac-LKKTETQ) is the conserved actin-binding motif spanning residues 17-23 of thymosin beta-4; in published in-vitro work this seven-residue core sequesters G-actin and is characterized as the region responsible for much of the parent protein's actin-regulation and cell-migration activity. As a short synthetic fragment it is studied as a lower-molecular-weight analog of full-length thymosin beta-4 in cytoskeletal-dynamics and tissue-remodeling assay systems.
Documentation
batch-linked COA, HPLC chromatogram and MS identity record for every production lot. Distribution scope confirmed before invoicing.
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Mass spectrometry identity confirmation against the Frag 17-23 (TB-500 Fragment 17-23, Ac-LKKTETQ) reference profile.
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Frag 17-23 is the short seven-residue active core (Ac-LKKTETQ, residues 17-23), whereas full-length thymosin beta-4 is a 43-residue protein. We supply both as separate research-use SKUs so labs can select the fragment or the full sequence, and specifications for each are stated on its own COA.
Each lot ships with a Certificate of Analysis including HPLC purity, mass-spec (ESI-MS or MALDI-TOF) identity confirmation, and appearance and water-content data. Additional documentation such as residual-solvent or endotoxin (only if specifically ordered and tested) testing is available on request.
Frag 17-23 is supplied as a lyophilized white powder, typically at least 99% by HPLC target, in 10mg vials. Purity threshold, counter-ion, and fill can be specified for OEM and private-label orders.
Catalog MOQ is 50 kits (500 vials) at 10mg. We manufacture for OEM and private-label programs, including custom vial fills, labeling, and bulk lyophilized peptide-powder supply under separate quotation.
Yes. Frag 17-23 is sold strictly for laboratory and in-vitro research use and is not a food, drug, cosmetic, or medical product. Buyers are responsible for compliance with all applicable import, handling, and end-use regulations in their jurisdiction.
Related compounds